EDMA

EDMA
Systematic (IUPAC) name
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-methylpropan-2-amine
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
Identifiers
ATC code none
PubChem CID 24257269
ChemSpider 23553090 YesY
Chemical data
Formula C12H17NO2
Molar mass 207.269 g/mol
  (verify)
This article is about a substituted amphetamine. For other uses, see EDMA (disambiguation).

3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is an entactogen drug of the amphetamine class.[1][2] It is an analogue of MDMA where the methylenedioxy ring has been replaced by an ethylenedioxy ring.[1][2] EDMA was first synthesized by Alexander Shulgin.[1] In his book PiHKAL, the dosage is listed as 150–250 mg, and the duration listed as 3–5 hours.[1] According to Shulgin, EDMA produces a bare threshold consisting of paresthesia, nystagmus, and hypnogogic imagery, with few to no other effects.[1] Scientific research has demonstrated that EDMA acts as a non-neurotoxic serotonin releasing agent with moderately diminished potency relative to MDMA, and with negligible effects on dopamine release.[2] Based on Shulgin's reports of essential inactivity at 150–250 mg, it may be more active at higher doses.

See also

References

  1. 1 2 3 4 5 Ann Shulgin; Alexander Shulgin (1991). Pihkal: A Chemical Love Story. Transform Press. ISBN 0-9630096-0-5.
  2. 1 2 3 McKenna DJ, Guan XM, Shulgin AT (March 1991). "3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine". Pharmacology, Biochemistry, and Behavior 38 (3): 505–12. doi:10.1016/0091-3057(91)90005-M. PMID 1829838.

External links


This article is issued from Wikipedia - version of the Monday, April 11, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.